Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700458 | 1.00 | ENPP2 (0.53) | ENPP2PRMT1PLAURAD51NPC1 | |
| SCHEMBL29360736 | 1.00 | ENPP2 (0.53) | ENPP2PRMT1PLAURAD51NPC1 | |
| SCHEMBL29366447 | 0.92 | ENPP2 (0.60) | ENPP2PRMT1PLAURAD51NPC1 | |
| SCHEMBL5694392 | 0.92 | ENPP2 (0.60) | ENPP2PRMT1PLAURAD51NPC1 | |
| SCHEMBL5694390 | 0.92 | ENPP2 (0.60) | ENPP2PRMT1PLAURAD51NPC1 | |
| SCHEMBL9360369 | 0.92 | PRMT1 (0.52) | ENPP2PRMT1PLAUNPC1RAB9A | |
| SCHEMBL9360377 | 0.92 | PRMT1 (0.52) | ENPP2PRMT1PLAUNPC1RAB9A | |
| SCHEMBL7219219 | 0.92 | PRMT1 (0.52) | ENPP2PRMT1PLAURAD51NPC1 | |
| SCHEMBL11169136 | 0.90 | ENPP2 (0.58) | ENPP2PRMT1RAD51NPC1RAB9A | |
| SCHEMBL29402666 | 0.89 | POLB (0.58) | ENPP2PRMT1RAD51NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9005988-B2 | Method to assess multiphase fluid compositions | LUX INNOVATE LIMITED (GB) | 2015-04-14 | — | — | US | claimed |
| US-20110151576-A1 | METHOD TO ASSESS MULTIPHASE FLUID COMPOSITIONS | LUX INNOVATE LIMITED (GB) | 2011-06-23 | — | — | US | claimed |
| US-20110104781-A1 | ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES | Life Technologies Corporation (US) | 2011-05-05 | — | — | US | claimed |
| US-20100233782-A1 | ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES | Life Technologies Corporation (US) | 2010-09-16 | — | — | US | claimed |
| WO-2010007390-A2 | METHOD TO ASSESS MULTIPHASE FLUID COMPOSITIONS | LUX INNOVATE LIMITED (GB) | 2010-01-21 | — | — | WO | claimed |
| EP-2118129-A2 | ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES | Life Technologies Corporation (US) | 2009-11-18 | — | — | EP | claimed |
| US-20090161828-A1 | ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES | LIFE TECHNOLOGIES (US) | 2009-06-25 | — | — | US | claimed |
| US-20080248565-A1 | ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES | INVITROGEN CORPORATION (US) | 2008-10-09 | — | — | US | claimed |
| WO-2008106660-A2 | ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES | INVITROGEN CORPORATION (US) | 2008-09-04 | — | — | WO | claimed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11921117-B2 | Characterization of subvisible particles using a particle analyzer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-05 | — | — | US | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3566649-B1 | DEVICES FOR BLOOD SAMPLING | YOURBIO HEALTH INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-6030768-A | Analysis of conformational changes in band 3 protein as a method for diagnosing Alzheimer's disease | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-02-29 | — | — | US | disclosed |
| US-5928841-A | Method of photoetching at 180 to 220 | KABUSHIKI KAISHA TOSHIBA (JP) | 1999-07-27 | — | — | US | disclosed |
| WO-1999013725-A1 | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-03-25 | — | — | WO | disclosed |
| US-5691101-A | NONTOXIC PHOTORESISTS FOR MANUFACTURE OF CATHODE RAY TUBES AND IMAGE PICKUP DEVICES, ACID GENERATING COMPOUND WHICH CATALYZES CROSSLINKING OR DECOMPOSITION OF RESIN | KABUSHIKI KAISHA TOSHIBA (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5007942-A | Light-polarizing films or sheets containing stilbene dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-16 | — | — | US | disclosed |
| EP-0374655-A1 | Light-polarising films or foils containing stilbene pigments | BAYER AG (DE) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | ENPP2 160/4885PRMT1 4858/4885PLAU 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.